| 2.65 0 (0%) | 11-29 11:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.34 | 1-year : | 3.9 |
| Resists | First : | 2.85 | Second : | 3.34 |
| Pivot price | 2.44 |
|||
| Supports | First : | 2.22 | Second : | 1.83 |
| MAs | MA(5) : | 2.7 |
MA(20) : | 2.4 |
| MA(100) : | 2.19 |
MA(250) : | 3.48  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 78.8 |
D(3) : | 83.6 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 8.81 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PSTX ] has closed below upper band by 26.1%. Bollinger Bands are 33.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.71 - 2.73 | 2.73 - 2.74 |
| Low: | 2.56 - 2.57 | 2.57 - 2.59 |
| Close: | 2.62 - 2.65 | 2.65 - 2.68 |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Fri, 17 Nov 2023
Is Poseida Therapeutics Inc (PSTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Thu, 09 Nov 2023
Poseida Therapeutics Provides Updates and Financial Results for ... - PR Newswire
Tue, 07 Nov 2023
Poseida Therapeutics to Present at Two Upcoming Investor ... - PR Newswire
Thu, 02 Nov 2023
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Mon, 09 Oct 2023
Poseida Therapeutics Announces Leadership Transition - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 28.2 (%) |
| Held by Institutions | 52.3 (%) |
| Shares Short | 3,030 (K) |
| Shares Short P.Month | 3,910 (K) |
| EPS | -1.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.28 |
| Profit Margin | -264.1 % |
| Operating Margin | -387.4 % |
| Return on Assets (ttm) | -25.1 % |
| Return on Equity (ttm) | -77.4 % |
| Qtrly Rev. Growth | -92 % |
| Gross Profit (p.s.) | -0.24 |
| Sales Per Share | 0.52 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | -0.7 |
| Price to Book value | 2.07 |
| Price to Sales | 5.12 |
| Price to Cash Flow | -4.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|